Broker Tips
Barclays raises target prices on Croda, Synthomer
Analysts at Barclays expect the European chemicals sector to post one of its strongest first quarters in some time, thanks to pre-buying as prices for raw materials rise and after product spreads widened to "remarkable" levels over the first three months of 2017.
Share buybacks at Aviva not a joke, Berenberg says
Analysts at Berenberg reiterated their 'sell' recommendation on Aviva shares, arguing that the insurer's balance sheet was overleveraged, its operating profits had been flattered by less prudence on reserves and its prospects for organic earnings growth was limited.
Broker tips: AstraZeneca, Hikma Pharmaceuticals
AstraZeneca's strategy of disposals and 'externalising' revenues from selling licensing rights to its drugs will hit revenues and earnings more than the market realises, Jefferies said on Monday, downgrading its rating on the shares to 'hold' from 'buy'.
Monday broker round-up
AstraZeneca: Jefferies downgrades to Hold with a target price of 5050p.
AstraZeneca slips on Jefferies downgrade over externalisation impact
AstraZeneca's strategy of disposals and 'externalising' revenues from selling licensing rights to its drugs will hit revenues and earnings more than the market realises, Jefferies said on Monday, downgrading its rating on the shares to 'hold' from 'buy'.
Hikma boosted by Numis upgrade to 'buy'
Hikma Pharmaceuticals got a boost on Monday as Numis upgraded the stock to 'buy' from 'add'.